Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | F2R | P25116 | 5/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361304 | 0.81 | SLC6A1 (0.50) | FFAR4SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL954535 | 0.81 | ITGB3 (0.56) | ITGB3ITGA2BF2RSLC6A1GABRA5 | |
| SCHEMBL23603991 | 0.80 | FFAR4 (0.40) | FFAR4 | |
| Hydrochloric Acid SCHEMBL3159636 | 0.79 | ITGB3 (0.54) | ITGB3ITGA2BF2RSLC6A1GABRA5 | |
| SCHEMBL16466404 | 0.78 | ALDH1A1 (0.39) | ADRA2C | |
| SCHEMBL27118478 | 0.77 | FFAR4 (0.35) | ADRA2CFFAR4 | |
| Acetic Acid SCHEMBL9210574 | 0.76 | ITGB3 (0.51) | ITGB3ITGA2BF2RSLC6A1GABRA5 | |
| SCHEMBL26105435 | 0.74 | KDM1A (0.33) | — | |
| SCHEMBL5495308 | 0.74 | ITGB3 (0.50) | ITGB3ITGA2BF2RSLC6A1GABRA5 | |
| SCHEMBL30864009 | 0.74 | KDM1A (0.33) | ITGB3ITGA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906542-B1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME (US) | 2019-08-07 | — | — | EP | disclosed |
| US-9708270-B2 | Substituted spiropiperidinyl compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2906542-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014059232-A2 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-04-17 | — | — | WO | disclosed |
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6528534-B2 | Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2002-01-31 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274672-A1 | SUBSTITUTED SPIROPIPERIDINYL COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR180, GPR88 | ITGB3 2393/4885ITGA2B 1793/4885ADRA2C 79/4885 |
| US-20020013325-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | ITGB3 57/4885ITGA2B 44/4885ADRA2C 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.